36365-79-4

Usage

Uses

Used in Pharmaceutical Research and Development:
(2-thioxo-4-thiazolin-4-yl)acetic acid is used as a building block for the synthesis of various biologically active molecules in pharmaceutical research and development. Its unique structure and reactivity make it an important component in the creation of new drugs and treatments.
Used in Medicine:
(2-thioxo-4-thiazolin-4-yl)acetic acid is used in medicine for its potential applications in the development of new drugs and treatments. Its interesting pharmacological properties make it a promising candidate for further research and development in the medical field.

InChI:InChI=1/C5H5NO2S2/c7-4(8)1-3-2-10-5(9)6-3/h2H,1H2,(H,6,9)(H,7,8)

Upstream product

• 38449-49-9 2-mercapto-4-ethoxycarbonylmethylthiazole 
• 38449-49-9 2-mercapto-thiazole-4-acetic acid,ethyl ester 
• 89910-38-3 (4-hydroxy-2-thioxo-thiazolidin-4-yl)-acetic acid ethyl ester 

Downstream Products

• 194929-94-7 (6R,7R)-3-(4-Carboxymethyl-thiazol-2-ylsulfanyl)-8-oxo-7-phenylacetylamino-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid benzhydryl ester 
• 1370256-65-7 2-{2-[6,7-bis(2-methoxyethoxy)quinazolin-4-ylthio]thiazol-4-yl}-N-(3-chlorophenyl)acetamide 
• 1370256-66-8 2-{2-[6,7-bis(2-methoxyethoxy)quinazolin-4-ylthio]thiazol-4-yl}-N-[3-(trifluoromethyl)phenyl]acetamide 
• 1370256-68-0 2-{2-[6,7-bis(2-methoxyethoxy)quinazolin-4-ylthio]thiazol-4-yl}-N-(3,5-dimethylphenyl)acetamide 
• 1370256-67-9 2-{2-[6,7-bis(2-methoxyethoxy)quinazolin-4-ylthio]thiazol-4-yl}-N-[4-(trifluoromethyl)phenyl]acetamide 

Relevant academic research and scientific papers

IDO inhibitors

Presently provided are methods for (a) modulating an activity of indoleamine 2,3-dioxygenase comprising contacting an indoleamine 2,3-dioxygenase with a modulation effective amount of a compound as described in one of the aspects described herein; (b) treating indoleamine 2,3-dioxygenase (IDO) mediated immunosuppression in a subject in need thereof, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (c) treating a medical conditions that benefit from the inhibition of enzymatic activity of indoleamine-2,3-dioxygenase comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; (d) enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent and a compound as described in one of the aspects described herein; (e) treating tumor-specific immunosuppression associated with cancer comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount of a compound as described in one of the aspects described herein; and (f) treating immunosuppression associated with an infectious disease, e.g., HIV-I infection, comprising administering an effective indoleamine 2,3-dioxygenase inhibiting amount a compound as described in one of the aspects described herein.

Thiazole- and imidazole-containing peptidomimetic inhibitors of protein farnesyltransferase

Mimetics of the C-terminal CAAX tetrapeptide of Ras protein were designed replacing internal dipeptide AA with 4-amino-2-phenylbenzoic acid and cysteine (C) with 2-amino-4-thiazolyl-, 2-mercapto-4-thiazolyl-, 2-mercapto-4-imidazolyl- and 2-methylmercapto-4-thiazolyl-acetic or propionic acid. The compound in which C is replaced by 2-amino-4-thiazolylacetic acid inhibited FTase activity in the low nanomolar range and showed antiproliferative effect on rat aortic smooth muscle cells interfering with Ras farnesylation. On the basis of these results, 2-aminothiazole can be considered as an alternative to heterocycles, such as pyridine and imidazole, normally used in FTase inhibitors designed as non-thiol CAAX mimetics.

Studies on anti-Helicobacter pylori agents. Part 3: A novel, efficacious cephem derivative, FR193879

The synthesis, therapeutic efficacy against H. pylori, and preliminary safety of the novel cephem derivative, FR193879 (8a) are described. Compound 8a having a (4-carbamoylmethylthiazol-2-yl)thio moiety at the 3-position and a phenylacetamido at the 7-position was found to have good safety showing a nontoxic dose of 100mg/kg in dogs in a 4-week repeat dose toxicity study and extremely potent therapeutic efficacy against H. pylori, showing 30 times superior activity compared to AMPC, and did not display cross-resistance with CAM or MNZ.